Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by Arbourmarkon Dec 16, 2020 11:02am
219 Views
Post# 32118437

News Release

News ReleaseI am struggling to understand AGN management and their decision to release yesterdays news release.

I have analyzed the trading prior to the halt. If you recall last Friday the share price began to run in the last 30 minutes. When the markets opened again Monday morning the shares continued to soar to .54 cents and the trading was halted at the request of the company upon news at .48 cents. This was not a halt initiated by IIROC, it was at the companies request.

We all know it was halted around 2pm and did not open again until Tuesday morning after the news release. We all know that they were finished with PHASE 2 and were anticipating either positive data or negative data.

I am not sure if other agrees but first off, why could they not have waited to release that fluffy news release after the markets closed. What was so earth shattering that it even required a halt? Why did they even release that news release with no data? Why not wait until you have material news. This is classic penny stock news release with no substance.

I know it is quite easy to be an arm chair quarterback and criticize management and their decisions.

I for one was dissappointed and obviously so were the markets as they punished the stock upon the open and continue to do so. To simply say the results were positive, what was the purpose with no supporting data. What was positive, they finished the phase 2 trial??

I have a position in another small cap pharma play ARCH, yesterday they released news, the stock was halted for 1 hour and it was material news with Federal Government providing $6.7 M in grant.

I am just scratching my head on AGN management decision to release the news that they did when the share price had momemtum prior to the release and investors were anticipating news release with supporting data or substance.

<< Previous
Bullboard Posts
Next >>